Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn

InvestorPlace04-30

These companies exhibit resilience and strategic adaptability under macroeconomic adversities. Procter & Gamble (PG): Derived solid organic revenue growth across regions in North America and Europe. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431317729?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-30 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431317729","market":"us","top_or_hot":-1,"title":"Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn","media":"InvestorPlace","content":"<div>\n<p>These companies exhibit resilience and strategic adaptability under macroeconomic adversities.\nProcter & Gamble (PG): Derived solid organic revenue growth across regions in North America and Europe.\n...</p>\n\n<a href=\"https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSlump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These companies exhibit resilience and strategic adaptability under macroeconomic adversities.\nProcter & Gamble (PG): Derived solid organic revenue growth across regions in North America and Europe.\n...</p>\n\n<a href=\"https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2552382215.SGD","symbol_name":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/","article_id":"2431317729","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431317729","pubTimestamp":1714475820,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Discover how these stocks may progress in consumer staples, health care, and tech sectors and outperform the S&P 500.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","JNJ":"强生","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","SPY":"标普500ETF","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4588":"碎股","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","03165":"华夏欧优股对冲","ASML":"阿斯麦","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC",".SPX":"S&P 500 Index","PG":"宝洁","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","BK4018":"居家用品","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","SG9999002232.USD":"Allianz Global High Payout USD","BK4147":"半导体设备","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2063271972.USD":"富兰克林创新领域基金","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4007":"制药","BK4558":"双十一","VOO":"Vanguard标普500ETF","BK4568":"美国抗疫概念","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","BK4559":"巴菲特持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4550":"红杉资本持仓","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H"},"translate_title":"低迷幸存者：3只股票将比标普500低迷持续更久","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOO":1,"ASML":1,"SPY":1,".SPX":1,"PG":1,"JNJ":1,"03165":0.6},"content_text":"These companies exhibit resilience and strategic adaptability under macroeconomic adversities.\nProcter & Gamble (PG): Derived solid organic revenue growth across regions in North America and Europe.\nJohnson & Johnson (JNJ): Holds solid growth in its medicine segment, including oncology and other therapeutic areas.\nASML (ASML): Secures significant order bookings, indicating strong product demand.\n\n\n\n\n\n \n\nSource: Dmitry Demidovich / Shutterstock\n\n\n\nIf you’re searching for stocks to outperform the S&P 500, look no further. Some stocks are more solid than others against market downturns and macro-economic uncertainty and have high chances of beating the S&P 500 index. Three of these stocks are listed here because of their fundamental resilience to market turbulence and their track record of steady performance. These companies have a lead across industries, including technology, healthcare, and consumer staples. They have certain traits that make them appealing investment choices during trying times.\nThe first demonstrates a substantial increase in organic sales throughout various geographic areas. This indicates consistent customer demand and successful marketing tactics. The second one is impressive due to its cutting-edge pharmaceutical section. This shows significant income streams and encourages development potential in therapeutic areas like cancer. Significant order bookings were made for the third one. This demonstrates the high demand for its cutting-edge lithography technique and offers future revenue predictability.\nThese businesses stand out for more reasons than just their track record; they also exhibit resilience and strategic flexibility in adversity.\nStocks to Outperform the S&P 500: Procter & Gamble (PG)\nSource: Jonathan Weiss / Shutterstock.comProcter & Gamble (NYSE:PG) has demonstrated a fundamentally progressive trajectory of organic sales growth in several geographical regions. Notably, over the last four quarters (Q3 fiscal 2024), North America has had a constant volume growth trend. This has supported a 3% increase in organic sales (in Q3), indicating a persistent customer demand. \nSimilarly, Procter & Gamble’s growth in market share within its target regions is impressive. Focus markets in Europe, for example, had a vital 7% gain in organic sales over the previous three months, supported by a 1% rise in value share. This increasing market share trend indicates Procter & Gamble’s successful tactics in identifying customer preferences and boosting sales growth in strategic areas.\nDespite economic difficulties throughout Latin America, especially in Argentina due to a large currency depreciation, Procter & Gamble achieved a solid 17% increase in organic sales. Effective pricing techniques to counter currency swings were primarily responsible for this growth.\nOverall, there are adversities in some markets, such as Greater China and portions of Europe and Asia Pacific. However, Procter & Gamble may sustain positive volume growth in these areas. \nJohnson & Johnson (JNJ)\nSource: Sundry Photography / Shutterstock.comThe progressiveness of Johnson & Johnson’s (NYSE:JNJ) medicine segment is based on its array of products. With $13.6 billion in global sales (Q1 2024), the category has a sizable top-line. Notably, operational sales growth, removing the impact of the COVID-19 vaccine, is at an exceptional 8.3%, even with a 4% fall outside of the U.S.\nAdditionally, the company’s considerable expansion in this market indicates that its concentration on oncology is paying off. TECVAYLI, CARVYKTI, and DARZALEX all show impressive sales gains over the prior year. For example, revenues at TECVAYLI increased from $63 million to $133 million. This demonstrates a successful introduction in the context of relapsed refractory material. Comparably, CARVYKTI’s revenues increased by more than double, from $72 million to $157 million. This results from increased capacity, sharp manufacturing practices, and strong demand. \nFinally, Johnson & Johnson has progressed beyond cancer to other therapeutic fields, such as immunology and pulmonary hypertension. Hence, the company’s solid lead in this market is reflected in its 22.4% rise in sales of pulmonary hypertension, driven by the favorable patient mix, share gains, and market growth for OPSUMIT and UPTRAVI.\nASML (ASML)\nSource: Ralf Liebhold / ShutterstockStrong demand for ASML’s (NASDAQ:ASML) products reflects its impressive order bookings, which totaled €3.6 billion in Q1 2024 alone. The backlog provides revenue visibility and stability for the next quarters and at the end of Q1 2024, it was estimated to be over €38 billion. Thus, ASML’s ability to secure orders well in advance is reflected in the significant backlog, which lays a strong foundation for sustainable growth. \nMoreover, ASML predicts increased revenue in 2024, especially in its EUV division. This is indicative of the growing use of advanced lithography technology. The NXE 3800E has been released, which offers notable performance gains over earlier versions. Furthermore, ASML is focusing on developing lithography technology to satisfy future semiconductor node requirements, meeting the needs of both logic and memory clients, reflected in the delivery of high-NA systems.\nLastly, EUV customers’ anticipated shift to the NXE:3800E highlights ASML’s capacity to please and hold onto its clientele by providing improved solutions. Overall, ASML’s proactive approach to engaging clients and easing their transition to advanced lithography technologies has resulted in high customer interest in the High NA Systems Lab. \nAs of this writing, Yiannis Zourmpanos held long positions in JNJ and ASML. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nYiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.Consumer Staples, Healthcare, Semiconductor, TechnologyBlue-Chip Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/04/slump-survivors-3-stocks-that-will-outlast-the-sp-500-downturn/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431317729"}